Skip to main content
SpringerLink
Log in

Economic Evaluations of Varicella Vaccination Programmes

A Review of the Literature

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Chickenpox infections are generally mild but due to their very high incidence among healthy children they give rise to considerable morbidity and occasional mortality. With the development of a varicella vaccine in the early 1970s and its progressive licensing in many countries, interest in the efficiency of varicella immunisation programmes grew. The objective of this review was to discuss the methodological aspects and results of published economic evaluations of varicella vaccination. From this, we attempted to make recommendations.

A computerised search was carried out; 17 full economic evaluations of varicella vaccination were retrieved. The review identified the methodological divergences and similarities between the articles in four areas: study design, epidemiological data, economic data and model characteristics. We assessed to what extent the applied methods conform to general guidelines for the economic evaluation of healthcare interventions and compared the studies’ results.

The desirability of a universal vaccination programme depends on whose perspective is taken. Despite variability in data and model assumptions, the studies suggest that universal vaccination of infants is attractive to society because large savings occur from averted unproductive days for parents. For the healthcare payer, universal vaccination of infants does not generate savings. Vaccination of susceptible adolescents has been proposed by some authors as a viable alternative; the attractiveness of this is highly dependent on the negative predictive value of anamnestic screening. Targeted vaccination of healthcare workers and immunocompromised individuals appears relatively cost effective. Findings for other target groups are either contradictory or provide insufficient evidence for any unequivocal recommendations to be made. High sensitivity to vaccine price was reported in most studies.

This review highlights that some aspects of these studies need to be further improved before final recommendations can be made. First, more transparency, completeness and compliance to general methodological guidelines are required. Second, because of the increasing severity of varicella with age, it is preferable and in some cases essential to use dynamic models for the assessment of universal vaccination strategies. Third, most studies focused on the strategy of vaccinating children only while their results depended heavily on disputable assumptions (regarding vaccine effectiveness and impact on herpes zoster). Since violation of these assumptions could have important adverse public health effects, we suggest pre-adolescent vaccination as a more secure alternative. This option deserves more attention in future analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Cohen JI, Brunell PA, Straus SE, et al. NIH conference. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130 (11): 922–32

    Article  CAS  PubMed  Google Scholar 

  2. Takahashi M, Otsukea T, Ikuno Y, et al. Live vaccine to prevent the spread of varicella in children in hospital. Lancet 1974; II: 1288–90

    Article  Google Scholar 

  3. Preblud SR. Varicella: complications and costs. Pediatrics 1986; 78 Suppl. 4: 728–34

    CAS  PubMed  Google Scholar 

  4. National Health and Medical Research Council. Draft 8th edition of the Australian immunisation handbook [online]. Available from URL: http://immunise.health.gov.au/handbook.htm [Accessed 2002 Oct 25]

  5. National Advisory Committee on Immunization (NACI). NACI update to statement on varicella vaccine [online]. Can Commun Dis Rep 2002; 28 (ACS-3): 1–8. Available from URL: http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/ccdr-rmtc/ [Accessed 2002 Oct 25]

    Google Scholar 

  6. Aberter AM, Baker L, Starr SE, et al. Combination measles, mumps, rubella, and varicella vaccine. Pediatrics 1986; 78 Suppl. 4: 742–7

    Google Scholar 

  7. White CJ, Stinson D, Staehle B. Measles, mumps, rubella and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 1997; 24: 925–31

    Article  CAS  PubMed  Google Scholar 

  8. Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd rev ed. Oxford: Oxford University Press, 1997

    Google Scholar 

  9. Rouse DJ, Gardner M, Allen SJ, et al. Management of the presumed susceptible varicella (chickenpox)-exposed gravida: a cost-effectiveness/cost-benefit analysis. Obstet Gynecol 1996; 87 (6): 932–6

    Article  CAS  PubMed  Google Scholar 

  10. Glantz JC, Mushlin AI. Cost-effectiveness of routine antenatal varicella screening. Obstet Gynecol 1998; 91 (4): 519–28

    CAS  PubMed  Google Scholar 

  11. Preblud SR, Orenstein WA, Koplan JP, et al. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985; 61 Suppl. 4: 17–22x

    PubMed  Google Scholar 

  12. Huse DM, Meissner HC, Lacey MJ, et al. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994; 124 (6): 869–74

    Article  Google Scholar 

  13. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994 Feb 2; 271 (5): 375–81

    Article  CAS  PubMed  Google Scholar 

  14. Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect Control Hosp Epidemiol 1997 Jul; 18 (7): 504–8

    Article  CAS  PubMed  Google Scholar 

  15. Gayman J. A cost-effectiveness model for analyzing two varicella vaccination strategies. Am J Health Syst Pharm 1998 Dec 15; 55 Suppl. 4: 4S–8S

    Article  Google Scholar 

  16. Lieu TA, Finkler LJ, Sorel ME, et al. Cost-effectiveness of varicella serotesting versus presumptive vaccination of schoolage children and adolescents. Pediatrics 1995 May; 95 (5): 632–8

    CAS  PubMed  Google Scholar 

  17. Smith WJ, Jackson LA, Watts DH, et al. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 1998; 92 (4 Pt 1): 535–45

    CAS  PubMed  Google Scholar 

  18. Burnham BR, Wells TS, Riddle JR. A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. Mil Med 1998 Sep; 163 (9): 631–4

    Article  CAS  PubMed  Google Scholar 

  19. Howell MR, Lee T, Gaydos CA, et al. The cost-effectiveness of varicella screening and vaccination in U.S. army recruits. Mil Med 2000 Apr; 165 (4): 309–15

    Article  CAS  PubMed  Google Scholar 

  20. Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. Am J Med 2000 Jun 15; 108 (9): 723–9

    Article  CAS  PubMed  Google Scholar 

  21. Kitai IC, King S, Gafni A. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clin Infect Dis 1993 Sep; 17 (3): 441–7

    Article  CAS  PubMed  Google Scholar 

  22. Beutels P, Clara R, Tormans G, et al. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996 Nov; 174 Suppl. 3: 335S–41S

    Article  Google Scholar 

  23. Gray AM, Fenn P, Weinberg J, et al. An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 1997 Oct; 119 (2): 209–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Díez Domingo J, Ridao M, Latour J, et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999 Mar 17; 17 (11–12): 1306–11

    Article  PubMed  Google Scholar 

  25. Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17 (2): 142–51

    Article  CAS  PubMed  Google Scholar 

  26. Scuffham P, Devlin N, Eberhart-Phillips J, et al. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 1999 Sep; 49 (6): 763–79

    Article  CAS  PubMed  Google Scholar 

  27. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000 Oct 14; 18 (5–6): 407–15

    Google Scholar 

  28. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20: 1113–25

    Article  CAS  PubMed  Google Scholar 

  29. Getsios D, Caro JJ, Caro G et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J 2002; 21: 542–7

    Article  PubMed  Google Scholar 

  30. Beutels P, Edmunds WJ, Antoñanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20 (1): 1–7

    Article  PubMed  Google Scholar 

  31. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health andmedical practices. N Engl J Med 1977; 296: 716–21

    Article  CAS  PubMed  Google Scholar 

  32. Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci 1983; 29 (3): 300–6

    Article  Google Scholar 

  33. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1: 71–6

    Article  CAS  PubMed  Google Scholar 

  34. Van Hout BA. Discounting costs and effects: a reconsideration. Health Econ 1998; 7: 581–94

    Article  PubMed  Google Scholar 

  35. Gold MR, Siegel JE, Russel LB, et al. Cost-Effectiveness in health and medicine. New York: Oxford University Press, 1996

    Google Scholar 

  36. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors [online]. Technology Appraisals Process Series No 5, 2001 Jun. Available from URL: http://www.nice.org.uk/ [Accessed 2001 Aug 17]

    Google Scholar 

  37. Gershon AA, Takahashi M, White CJ. Varicella vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadephia: WB Saunders Co, 1999: 475–507

    Google Scholar 

  38. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatrics 1997; 130: 759–65

    Article  CAS  Google Scholar 

  39. Fairley CK, Miller E. Varicella-zoster virus epidemiology: a changing scene? J Infect Dis 1996; 174 Suppl. 3: S314–9

    Article  PubMed  Google Scholar 

  40. Centre for Disease Control and Prevention. Prevention of varicella: recommendations of the advisory Committee on Immunisation Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45 (RR-11): 2–3

    Google Scholar 

  41. Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis 2000; 182: 383–90

    Article  CAS  PubMed  Google Scholar 

  42. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278 (18): 1495–9

    Article  CAS  PubMed  Google Scholar 

  43. Vázquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344 (13): 955–60

    Article  PubMed  Google Scholar 

  44. Buchholz U, Moolenaar R, Peterson C, et al. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics 1999; 104 (3 Pt 1): 561–3

    Article  CAS  PubMed  Google Scholar 

  45. Clements DA, Moreira SP, Coplan PM, et al. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 1999; 18 (12): 1047–50

    Article  CAS  PubMed  Google Scholar 

  46. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000 Sep; 284 (10): 1271–9

    Article  CAS  PubMed  Google Scholar 

  47. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2001; 19: 916–23

    Article  Google Scholar 

  48. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310 (22): 1409–15

    Article  CAS  PubMed  Google Scholar 

  49. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96: 102–9

    Article  CAS  PubMed  Google Scholar 

  50. Oostenbrink JB, Koopmanschap MA, Rutten FH. Standardisation of costs; the Dutch manual for costing in economic evaluations. PharmacoEconomics 2002; 20 (7): 443–54

    Article  PubMed  Google Scholar 

  51. Jefferson T, Mugford M, Gray A, et al. An exercise on the feasibility of carrying out secondary economic analysis. Health Econ 1996; 5: 155–65

    Article  CAS  PubMed  Google Scholar 

  52. Tennenberg AM, Brassard JE, Van Lieu J, et al. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect Control Hosp Epidemiol 1997 Jun; 18 (6): 405–11

    Article  CAS  PubMed  Google Scholar 

  53. Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89

    Article  CAS  PubMed  Google Scholar 

  54. Weinstein MC. From cost-effectiveness ratio to resource allocation: where to draw the line? In: Sloan FA, editor. Valuing health care. New York: Cambridge University Press, 1995: 77–97

    Chapter  Google Scholar 

  55. Gerard K, Mooney G. QALY league tables: handle with care. Health Econ 1993; 2: 59–64

    Article  CAS  PubMed  Google Scholar 

  56. Brouwer WBF, Koopmanschap MA, Rutten FH. Productivity costs measurement through quality of life?: a response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253–9

    Article  CAS  PubMed  Google Scholar 

  57. Meltzer D, Johannesson M. Inconsistencies in the “Societal Perspective” on costs of the panel on cost-effectiveness in health and medicine. Med Decis Making 1999; 19 (4): 371–7

    Article  CAS  PubMed  Google Scholar 

  58. Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunisation of preschool children in the united states. Am J Epidemiol 1994 Jul; 140 (2): 81–104

    Article  CAS  PubMed  Google Scholar 

  59. Brisson M, Edmunds WJ, Gay NJ, et al. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 2000; 18: 2775–8

    Article  CAS  PubMed  Google Scholar 

  60. Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 1992; 108: 513–28

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nature Med 2000; 6 (4): 541–4

    Article  CAS  Google Scholar 

  62. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18: 3263–82

    Article  CAS  PubMed  Google Scholar 

  63. Anderson R, Nokes DJ. Mathematical models of transmission and control. In: Holland WW, Detels R, Knox EG, editors. Oxford textbook of public health. Oxford: Oxford University Press, 1996: 689–719

    Google Scholar 

  64. Halloran ME. Epidemiologic effect of varicella vaccination. Infect Dis Clin North Am 1996; 10 (3): 631–55

    Article  CAS  PubMed  Google Scholar 

  65. Beutels P. Economic evaluations of hepatitis B immunisation: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74

    Article  CAS  PubMed  Google Scholar 

  66. Lieu TA, Black SB, Takahashi H, et al. Varicella serology among school age children with a negative or uncertain history of chickenpox. Pediatr Infect Dis J 1998 Feb; 17 (2): 120–5

    Article  CAS  PubMed  Google Scholar 

  67. Gallager J, Quaid B, Cryan B. Susceptibility to varicella zoster virus infection in health care workers. Occup Med 1996; 46 (4): 289–92

    Article  Google Scholar 

  68. Vandersmissen G, Moens G, Vranckx R, et al. Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study. Occup Environ Med 2000; 57: 621–6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Brunell PA, Wood D. Varicella serological status of health care workers as guide to whom to test or immunise. Infect Control Hosp Epidemiol 1999 May; 20 (5): 355–7

    Article  CAS  PubMed  Google Scholar 

  70. Ferson MJ, Bell SM, Robertson PW. Determination and importance of varicella immune status of nursing staff in a children’s hospital. J Hosp Infect 1990; 15: 347–51

    Article  CAS  PubMed  Google Scholar 

  71. Seidman DS, Stevenson DK, Arvin AM. Varicella vaccine in pregnancy. BMJ 1996; 313: 701–2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Nathwani D, Maclean A, Conway S, et al. Varicella infections in pregnancy and the newborn. J Infect 1998; 36 Suppl. 1: 59S–71S

    Article  Google Scholar 

  73. Pauly MV. Valuing health care benefits in money terms. In: Sloan FA, editor. Valuing health care. New York: Cambridge University Press, 1995: 99–122

    Chapter  Google Scholar 

  74. Beutels P, Van Damme P, Van Doorslaer E. Program evaluation of universal varicella vaccination in Belgium. ESOC-report No 36. Antwerp: University of Antwerp-UIA, 2000 Sep

    Google Scholar 

  75. Brisson M, Edmunds WJ, Gay NJ, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125: 651–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was financed by a research grant from the Fund for Scientific Research (contract no. G.0023.01) and the Fund for Specific Research from the University of Antwerp, Belgium (BOF-UA-2001). The authors have no conflict of interests to declare that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Department of Epidemiology and Social Medicine, Centre for the Evaluation of Vaccination, University of Antwerp, Universiteitsplein 1, Antwerp, 2610, Belgium

    Nancy Thiry, Philippe Beutels & Pierre Van Damme

  2. Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

    Eddy Van Doorslaer

Authors
  1. Nancy Thiry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Beutels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Van Damme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eddy Van Doorslaer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy Thiry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thiry, N., Beutels, P., Van Damme, P. et al. Economic Evaluations of Varicella Vaccination Programmes. Pharmacoeconomics 21, 13–38 (2003). https://doi.org/10.2165/00019053-200321010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321010-00002

Keywords

Search

Navigation